Advertising
Showing 1 to 15 of 740 entries

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Apr 19/22, Up 9.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE is progressing well. We now recommend trailing up the stop (from $42) to $48.
biotechnology / pharmaceutical
BUY
Diversified business, gold standard. PFE is making acquisitions, building out the pipeline from Covid cashflow wins. Good mRNA franchise, benefits of diversity, plus management team executing on pipeline of acquisitions.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick May 28/20, Up 45%) A defensive. Back then, they were working on the vaccine and luckily theirs was the most effective. He trimmed at $55, but still likes and holds it. The company has in the past struggled to build a pipeline of drugs. This morning they announced they will buy a company that treats migraines. They're spending $11 billion on their pipeline, which is promising. They earned $25 billion revenues in vaccines in 2021. Pays a great dividend. Remains a core holding.
biotechnology / pharmaceutical
COMMENT
They report Tuesday. They've made a lot of money during the pandemic. He hopes they buy another drug company to make up for looming patent explorations in the coming years. Shares were crushed today. Good yield and trades at 6x earnings, though.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly PFE has a long pipeline of new drugs focusing on oncology, rare diseases and vaccines, generating over $50 billion in annual sales. It trades at 13x earnings compared to peers at 20x. Latest reported earnings beat expectations by 27% and supports a ROE over 34%. Its dividend is backed by a payout ratio under 40% of cashflow. It is managing its cash reserves conservatively, maintaining a good war chest, while still retiring debt. We would recommend a stop loss at $42.00, looking to achieve $60.50 -- upside potential of 19%. Yield 3.0% (Analysts’ price target is $60.47)
biotechnology / pharmaceutical
DON'T BUY
Has done extremely well with Covid solutions. Not inexpensive for its growth rate. A concern for the stock, though not for humanity, is this opportunity will exhaust itself. Not a bad name if Covid will be a chronic situation. All pharma races the patent clock. He'd prefer MRK.
biotechnology / pharmaceutical
HOLD
Value and price momentum score well. High ROE, 13x price to earnings. Healthy yield of 3%, very reasonable payout ratio. You can own it through the cycles.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Sep 24/20, Up 28.9%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE has triggered its stop at $46. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 23%, when combined with the previous recommendation to cover half.
biotechnology / pharmaceutical
HOLD
Suffered recently a bit, as shine from Covid has worn off. Great defensive growth name. Likes healthcare in general. Don't sell it to buy LLY, but nothing against LLY. Trades at 6x forward earnings. Great cardio drug that could be a gamechanger, strong pipeline. Yield is 3.5%.
biotechnology / pharmaceutical
HOLD
Has recently sold shares in company. Long term, pandemics will remain a fact of life. Has good pipeline of new drugs being developed.
biotechnology / pharmaceutical
TOP PICK
R&D has become much more concentrated. Cashflow windfall being used to expand pipeline. CEO has done exceptional job navigating the vaccine environment. Tuck-in acquisitions. Executing well, deserves the multiple bump. Yield is 3%. (Analysts’ price target is $58.53)
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Sep 24/20, Up 51.5%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with PFE is progressing well. We now recommend tailing up the stop (from $42) to $46.
biotechnology / pharmaceutical
TOP PICK
One of the world's largest biopharma companies. Expected revenue of 97B USD this year. Likes it because of its rapidly improving pipeline, especially the cardio drug. Vaccine will produce cashflow windfalls over the near term, plus lots of runway. Continuing shots needed, anti-viral pill will be in high demand. Good valuation. Yield is 2.86%, expected to grow. (Analysts’ price target is $56.61)
biotechnology / pharmaceutical
SELL
Leadership position in vaccine fight. If you invest here, and pandemic goes away, PFE's fortunes could regress to the mean. It won't have the wind at its back anymore. The uncertainty makes him pass.
biotechnology / pharmaceutical
DON'T BUY
He stays away from drug companies, always forced to do acquisitions. Costly and competitive business. Pressures from government. Boost from pandemic, and this will continue. Reasonable valuation. He prefers medical devices, where you don't need a PhD to understand what's coming next. Attractive yield about 3%.
biotechnology / pharmaceutical
Showing 1 to 15 of 740 entries

Pfizer Inc(PFE-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 15

Neutral - Hold Signals / Votes : 4

Bearish - Sell Signals / Votes : 6

Total Signals / Votes : 25

Stockchase rating for Pfizer Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Pfizer Inc(PFE-N) Frequently Asked Questions

What is Pfizer Inc stock symbol?

Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N

Is Pfizer Inc a buy or a sell?

In the last year, 25 stock analysts published opinions about PFE-N. 15 analysts recommended to BUY the stock. 6 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Pfizer Inc.

Is Pfizer Inc a good investment or a top pick?

Pfizer Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Pfizer Inc.

Why is Pfizer Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Pfizer Inc worth watching?

25 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.

What is Pfizer Inc stock price?

On 2022-05-27, Pfizer Inc (PFE-N) stock closed at a price of $53.91.